LEE'S PHARM publishes 2025 Annual Report & Circular and switches fully to electronic dissemination

Bulletin Express
Apr 24

Lee’s Pharmaceutical Holdings Limited (LEE'S PHARM) announced on 24 April 2026 that its latest Annual Report and related Circular have been released in both English and Chinese on the HKEXnews website (www.hkexnews.hk) and the company’s site (http://www.leespharm.com). Printed copies can be requested free of charge through the Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, by email (leespharm.ecom@computershare.com.hk) or post (17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong).

In line with the HKEX paperless listing regime that took effect on 31 December 2023, LEE'S PHARM has adopted electronic dissemination for all future corporate communications, including annual and interim reports, meeting notices, circulars and proxy forms. Both language versions will be accessible online, replacing routine mailings.

Non-registered shareholders are advised to provide functional email addresses to their intermediaries—banks, brokers, custodians, nominees or HKSCC Nominees Limited—to receive electronic notifications. Until an email address is registered, these investors must check the company and HKEXnews websites proactively; actionable corporate communications will continue to be sent in printed form during this interim period.

Shareholders preferring hard copies of future documents can submit the supplied reply form or email the registrar with their name, address and request. Enquiries may be directed to the registrar at +852 2862 8688 during business hours (Monday–Friday, 9:00 a.m.–6:00 p.m., Hong Kong time).

The board is chaired by Ms. Lee Siu Fong, who signed off on the notification. All measures aim to enhance communication efficiency while supporting HKEX’s sustainability objectives through reduced paper usage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10